GeneReach Biotechnology Corp. (TPEX:4171)
Taiwan · Delayed Price · Currency is TWD 21.95
+0.45 (2.09%)
Jan 22, 2026, 12:59 PM CST
GeneReach Biotechnology Market Cap
GeneReach Biotechnology has a market cap or net worth of 1.24 billion as of January 21, 2026. Its market cap has decreased by -20.03% in one year.
Market Cap
1.24B
Enterprise Value
1.21B
Revenue
215.32M
Ranking
n/a
PE Ratio
n/a
Stock Price
21.95
Market Cap Chart
Since November 19, 2012, GeneReach Biotechnology's market cap has decreased from 1.27B to 1.24B, a decrease of -2.51%. That is a compound annual growth rate of -0.19%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 21, 2026 | 1.24B | 14.36% |
| Dec 31, 2025 | 1.08B | -34.10% |
| Dec 31, 2024 | 1.65B | -27.38% |
| Dec 29, 2023 | 2.27B | -25.28% |
| Dec 30, 2022 | 3.03B | -20.04% |
| Dec 30, 2021 | 3.79B | -27.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Enimmune corporation | 1.51B |
| Abnova (Taiwan) | 1.47B |
| Meribank Biotech | 1.35B |
| Lukas Biomedical | 1.26B |
| Taiwan Advance Bio-Pharmaceutical | 1.08B |
| Level Biotechnology | 1.07B |
| Holy Stone Healthcare | 1.07B |
| Neith | 1.02B |